New drugs in recurrent high grade gliomas
Related Experiment Video
Updated: Oct 15, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
A A Brandes1, L M Pasetto, S Monfardini
1Divisione di Oncologia Medica, Azienda Ospedale, Università, Padova, Italia. brandes@ux1.unipd.it
Background:
The incidence of Central Nervous System (CNS) neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurrence, the treatment is problematic; chemotherapy is experimental, primarily because the response is palliative and of limited duration.
Materials And Methods:
This article analyzes the new drugs that have been introduced for the treatment of these patients in recent years, the objective response, the TTP and the MST.
Results:
The most encouraging results to date come from studies of temozolomide, which is one of the most active and best tolerated drugs in recent years.
Conclusion:
New approaches to chemotherapy treatment are necessary. Enrollment of patients into rigorous, well-conducted, clinical trials, both at tumor diagnosis and after tumor recurrence, will generate new information regarding investigational therapies and may offer improved therapies for patients with malignant gliomas.
